NCT06341660Recruiting

To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)

Name: Clinical Trial NCT06341660
Creator: Guangzhou Institute of Respiratory Disease
Keywords: Non-small Cell Lung Cancer, cadonilimab, Phase 2, drug, clinical trial, China

A Single-arm Pilot Study of Patients With Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC) With KEAP1 Mutation Treated With Carbonizumab Combined With Chemotherapy as the First-line Treatment

Guangzhou Institute of Respiratory DiseasePhase 2ClinicalTrials.govdrug

Verified

Study focus

Disease/Condition: Non-small Cell Lung Cancer
Drug/Device/Intervention: cadonilimab
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Guangzhou Institute of Respiratory Disease
Location: Guangdong, China

Timeline & enrollment

Phase: Phase 2
Start date: May 25, 2023
End date: Jul 01, 2025
Enrollment: 30 participants

Primary outcome

Safety assessments and ORR

Summary

To evaluate the safety and tolerability of carbognilumab combined with chemotherapy as first-line treatment in patients with KeAP1-mutated advanced or postoperative recurrent non-small cell lung cancer.

ICD-10 classifications

Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06341660
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06341660 through Pure Global AI's free database. This Phase 2 trial is sponsored by Guangzhou Institute of Respiratory Disease and is currently Recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.